Metformin activates the AMPK/mTOR signaling pathway in a dose-dependent manner, which in turn induces Beclin-1-dependent autophagy and ultimately inhibits the malignant phenotype and exerts antitumor activity in GC cells, which provides a new therapeutic idea for GC (Liu S. et al., 2020). This evidence concerns the gene MTOR and gastric cancer.